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Abstract
Background: Cutaneous leishmaniasis (CL) is treated with parenteral drugs for decades with decreasing rate cures.
Miltefosine is an oral medication with anti-leishmania activity and may increase the cure rates and improve compliance.
Methodology/Principal Findings: This study is a randomized, open-label, controlled clinical trial aimed to evaluate the
efficacy and safety of miltefosine versus pentavalent antimony (Sbv) in the treatment of patients with CL caused by
Leishmania braziliensis in Bahia, Brazil. A total of 90 patients were enrolled in the trial; 60 were assigned to receive
miltefosine and 30 to receive Sbv. Six months after treatment, in the intention-to-treat analyses, the definitive cure rate was
53.3% in the Sbv group and 75% in the miltefosine group (difference of 21.7%, 95% CI 0.08% to 42.7%, p = 0.04). Miltefosine
was more effective than Sbv in the age group of 13–65 years-old compared to 2–12 years-old group (78.9% versus 45%
p = 0.02; 68.2% versus 70% p = 1.0, respectively). The incidence of adverse events was similar in the Sbv and miltefosine
groups (76.7% vs. 78.3%). Vomiting (41.7%), nausea (40%), and abdominal pain (23.3%) were significantly more frequent in
the miltefosine group while arthralgias (20.7%), mialgias (20.7%) and fever (23.3%) were significantly more frequent in the
Sbv group.
Conclusions: This study demonstrates that miltefosine therapy is more effective than standard Sbv and safe for the
treatment of CL caused by Leishmania braziliensis in Bahia, Brazil.
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Introduction
The principal species causing cutaneous leishmaniasis (CL) in
Brazil is Leishmania braziliensis which most often leads to a
cutaneous form of the disease characterized by one or more
ulcers with raised borders, most frequently located on the upper
and lower extremities, but also found on the head, face, and trunk
[1,2]. Although CL is a self-limited disease, approximately 3 to 5%
of subjects infected with L. braziliensis will eventually develop
mucosal disease or disseminated leishmaniasis, both considered
severe forms of leishmaniasis [2–4].
Pentavalent antimony (Sbv) by intramuscular or intravenous
route remains the first-line drug for the treatment of CL, a therapy
that is moderately toxic and difficult to administer in poor rural
areas. In an endemic area of L. braziliensis transmission in Bahia,
Brazil, cure rates after Sbv therapy are becoming increasingly
lower and vary from 50% to 90% [5–7]. Factors contributing to
this variability are not yet fully understood. The development of
parasite resistance [8] to a drug used for decades and irregular
adherence by the patients due to the daily schedule of parenteral
route during 20 days, could be main factors in determining the
increasingly failure rate to Sbv [5–7]. Other alternative drugs like
pentamidine and amphothericin B are also of parenteral use and
the former may require hospitalization.
Miltefosine, a phosphatidylcholine analogue, is an active
antileishmanial oral drug used for the treatment of visceral
leishmaniasis in India [9]. The clinical efficacy of miltefosine for
New World CL was investigated in trials conducted in Central and
South America. The cure rates varied from one leishmania species
to another, with L. panamensis having 82% of cure rate, L. mexicana
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60% and L braziliensis 33% respectively [10]. More recently in CL
caused by L. braziliensis in patients from Bolivia, Soto et al reported
a 88% cure rate [11]. These data shows that CL cure rate upon
miltefosine treatment varies among Leishmania species and also
between the same species from different endemic areas. Accord-
ingly, it is demonstrated that different treatment outcome after
antimony therapy is found in CL caused by L. braziliensis from
different endemic regions in Brazil [5,6,12]. There is no data
about the use of miltefosine in CL caused by L. braziliensis in Brazil,
where this species is considered the most aggressive and prevalent
agent of the disease [13].
This randomized and controlled trial evaluated the efficacy and
safety of miltefosine versus meglumine antimoniate (Sbv) for the




This trial has been conducted according to the principles
expressed in the Declaration of Helsinki. Prior to enrollment in the
study, all patients received a written copy of study policy which
was reviewed with them individually by an independent party. A
written informed consent was obtained for all adult patients, and
from parents or guardians of minors. This study was approved by
the Ethics Committee of the Federal University of Bahia, in
Salvador, Brazil (CEP/MCO/UFBA-Par/Res 034/2007).
Endemic area
All subjects were recruited at the health post of Corte de Pedra,
located 260 km southeast of Salvador, the capital of Bahia, Brazil.
This clinic is a referral center for the diagnosis and treatment of
CL, with an average of 1,000 new cases per year. L. braziliensis has
been the unique causal agent identified in this area in the last 15
years [14].
Patient selection
The criteria used for the diagnosis of CL were the presence of a
typical ulcerated lesion and a positive Montenegro intradermal
skin test in a subject living in the endemic area. A typical CL
ulcerated lesion is characterized by a round shape and raised
borders associated with regional adenopathy. This classical clinical
picture together with a positive leishmania skin test is highly
specific for CL in the endemic area [2,5]. Patients were then
selected based on the following inclusion criteria: 1) age between 2
and 65 years; 2) a maximum of 5 ulcers with no more than 2 body
regions involved; 3) lesion size between 10 and 50 mm in a single
dimension; and 4) a period of less than 90 days from the onset of
the first ulcer. All subjects were submitted to a punch biopsy to
obtain material for leishmania culture and PCR. Patients with a
prior history of CL or antimony use, patients with evidence of
mucosal or disseminated disease, pregnant or breastfeeding
mothers, and patients with HIV or any systemic severe disease
were excluded. A total of 90 patients were enrolled in the study.
Group Assignment
A randomization table was obtained with Statacorp LP 9, Texas
USA. Group assignments were made after assessment that patient
had met all eligibility criteria and no patients were withdrawn after
randomization because of ineligibility. The 90 patients were
randomly assigned at a rate of 2:1 allocation to receive miltefosine
for 28 days or Sbv for 20 days in two age groups (2–12 years-old
and 13–65 years-old).
Intradermal skin test
The Leishmania antigen used for intradermal skin testing was
obtained from Leishmania amazonensis strain (MHOM-BR-86BA-
125). The volar surface of the left forearm was injected with 25 mg
of antigen in 0.1 mL of distilled water, and the largest diameter of
induration was measured at 48–72 hours. The test was considered
positive for induration greater than 5 mm.
Parasitology
Parasite Culture. Needle aspiration of a skin lesion was
performed, and aspirates were cultured in Nicolle-McNeal-Novy
medium overlaid with modified liver infusion triptase medium.
Cultures were kept at 25uC and examined twice weekly. Isolates
were characterized by use of a panel of monoclonal antibodies.
PCR for leishmania DNA
DNA isolation was carried out from biopsy samples using the
Wizard Genomic DNA purification kit (Promega Corporation –
USA). Purified DNA was resuspended in TE buffer and stored
frozen at 220uC until use. Detection of the subgenus Viannia
applied the primers 59-GGGGTTGGTGTAATATAGTGG-39
and 59-CTAATTGTGCACG-39. For Leishmania genus detection
we have used the primers 59-(G/C)(G/C)(C/G)CC(A/C)CTAT(A/
T)TTA CAC CAA CCC C-39 and 59-GGG GAG GGG CGT-39.
Amplification mixes consisted of 25 pmol each primer; 1.2 mM
MgCl2; 0.2 mM dNTP; 2.5 U Taq DNA polymerase; 106 PCR
buffer; 2 uL of target DNA. Amplifications were carried out in a
Veriti 96-well thermal cycler (Applied Biosystems – USA). Viannia
detection applied 35 cycles of 1 minute at 94uC, 1 minute at 60uC
and 1 minute at 72uC. Amplicons were fractionated in 1.3% agarose
gels, stained with ethidium bromide and photographed under UV
light using a UVP Vision Works LS apparatus (UVP – USA). The
Leishmania specific band consists of 120 base pairs, and that for
Viannia of 750 base pairs.
Drug administration
All study volunteers were treated as outpatients. Miltefosine
(Impavido, Zentaris GmbH) was supplied in blisters containing
Author Summary
Cutaneous leishmaniasis (CL) is characterized by skin
ulcerations and occurs in rural poor areas of developing
countries. It is treated with daily injections of antimony for
20 days, which is associated with irregular use and
increasingly lower cure rates. Miltefosine is an oral
medication with activity against the agent of CL (Leish-
mania). We have studied the efficacy and safety of
miltefosine compared with antimony in patients with CL
caused by Leishmania braziliensis in Bahia, Brazil. A total of
90 patients participated; 60 received miltefosine and 30
were treated with antimony. Six months after treatment,
75% of patients treated with miltefosine were cured,
compared with 53% of the patients in the antimony group,
a difference considered significant (p = 0.04). We also
found that miltefosine was more effective than antimony
in adults than in children. The incidence of side effects was
similar with both drugs (76.7% vs. 78.3%), but all patients
were able to finish the treatments. Our study shows that
miltefosine is more effective than antimony for the
treatment of CL in Bahia, Brazil and can contribute to the
control of this disease due to its activity and easier
administration.
Miltefosine for L. braziliensis CL
www.plosntds.org 2 December 2010 | Volume 4 | Issue 12 | e912
10 mg or 50 mg capsules. Meglumine antimoniate (Glucantime,
Aventis) was supplied in vials of 5 ml containing 81 mg/Sbv/ml.
Miltefosine was administered orally at the total target daily dosage
of 2.5 mg/kg of body weight (maximum daily dose of 150 mg) for
28 consecutive days. Daily dose was divided in two or three
intakes, given always with meals according to the following weight
scale: patients with$15 kg and#29 kg - total dose of 50 mg/day;
patients with $30 kg and #45 kg - total dose of 100 mg/day;
patients with $46 kg - total dose of 150 mg/day. Meglumine
antimoniate (Sbv) was administered intravenously at a dose of
20 mg Sbv/kg/day for 20 consecutive days (maximum daily dose
of 3 ampoules or 1215 mg/Sbv). At every weekly visit patients
returned the blisters for verification of regular use and adherence.
Sbv was administered daily in health posts near from patient’s
home. In these cases the administration’s date and dosage were
registered and signed by the health care provider.
All women in child bearing age were submitted to beta HCG
test to exclude pregnancy. The use of a parenteral contraceptive
during and for 2 months after treatment was done in all women in
child bearing age.
Study Procedures
Complete hemogram, aminotransferases (AST, ALT), alkaline
phosphatase, potassium, sodium, urea, creatinine, and urine
chemistry were determined in all patients on day -1, weekly
thereafter up to the end of therapy, and after 15 and 30 days of the
end of therapy. Those with abnormal parameters were followed-
up until normalization. At each weekly return for drug
dispensation patients were monitored for adverse events (AE).
Bidirectional measurements of ulcers were taken of the patients’
lesions at the initial visit, and at each follow-up visit with
standardized caliper. The area involved was calculated as the
product of the two measurements. A standardized digital
photograph was also taken from each patient’s lesions at the same
time points.
Patients were seen for follow-up at 2 weeks, 1, 2, 4 and 6 months
post-therapy. In the event that a patient did not return for follow-
up at the specified time, visits were conducted in the patient’s
home in the same day or within 7 days of the missed appointment.
Clinical endpoints criteria. Primary end point: cure at 6
months after the end of therapy. Secondary end-points: a) cure at
2 months after the end of therapy; b) data from clinical and
laboratorial adverse events. All lesions were also categorized as
either active or healed (cured) at follow-up visits. Only lesions with
complete re-epithelialization, without raised borders, infiltrations
or crusts were considered healed. Evaluation of the lesions was
performed by 2 clinicians (LHG, EMC) who were unaware of the
group assignment of all patients.
Clinical and laboratory AE were graded according to the
Common Terminology Criteria for Adverse Event v3.0 (CTCAE)
of the National Cancer Institute (ctep.cancer.gov/protocolDeve-
lopment/electronic_applications/docs/ctcaev3.pdf).
Statistical Analysis
The results are presented as proportions, interquartile ranges
(IQR), 95% confidence intervals (95% CI), means and standard-
deviations (SD). The normally distributed variables were com-
pared using the t test. The proportions were compared with the
Chi-square or Fisher test when appropriate.
The sample size of 90 patients was obtained by calculating the
number of participants needed for 80% power (b= 0.2) to detect
an absolute difference as large as 25% in the rate of cure between
the two treatment groups with a statistical significance of 5%
(a= 0.05). The intention-to-treat (ITT) analysis was used to
calculate the cure rates. All statistical analyses were performed
with the software SPSS 9.0 for Windows. A value of p,0.05
established the level of statistical significance.
Results
From the 244 CL patients screened from July 2007 and August
2008, 154 subjects met the inclusion criteria, 90 were included in
the trial and completed the treatment, and 87 were followed for
the entire 6 months after therapy, up to March 2009 (Figure 1).
The patients ranged in age from 4 to 65 years with the mean age
of 22615 years, which did not differ significantly between the two
treatment groups (p = 0.85). Overall, there was a predominance of
male patients (67.8% vs. 32.2%), and there were statistically more
males in the miltefosine group than in the Sbv group (75.0% vs.
53.3%, p = 0.04). The majority presented with a single lesion
(76.7%), and significantly more patients in the miltefosine group
had $2 lesions (30% vs. 10%, p = 0.04). The lesion with the
greatest area at presentation was considered to be the main lesion.
The main lesion area was not different between treatment groups
(410.6 vs. 461.2 mm2, p = 0.47). The clinical characteristics of
patients in the two treatment groups and age groups (2–12 years
and 13–65 years) are shown in Table 1. A positive culture for
leishmania promastigotes was obtained in 52 out of 90 patients
(57.7%). L braziliensis was identified in 41 obtained samples from
biopsy by PCR. In 26 patients (28.8%) neither PCR nor culture
identified leishmania.
Efficacy
Two months after the end of the treatment, 60% (18/30) of
patients in the Sbv group had cured lesions, compared with 81.7%
(49/60) in the miltefosine group. The cure rates at 6 months of
follow-up were 53.3% (16/30) in the Sbv group and 75% (45/60)
in the miltefosine group (p = 0.04) (Table 2). The absolute
difference was 21.7% (95% CI 0.08% to 42.7%). The mean time
to cure was 75615 days in the Sbv group and 73617 days in the
miltefosine group (p = 0.63).
In age groups 2–12 years-old and 13–65 years-old cure rates at
6 months for miltefosine and Sbv were 68.2% (15/22) versus 70%
(7/10) (p = 1.0), and 78.9% (30/38) versus 45% (9/20) (p = 0.02),
respectively.
Two patients (one from miltefosine group and the other from
Sbv group) were lost for follow-up after the end of the treatment.
One patient in the miltefosine group was excluded by irregular use
of the medication.
Relapses occurred in both groups (two patients treated with Sbv
and four patients treated with miltefosine) between the 2 months
and 6 months after the end of the treatment. In four patients
(miltefosine = 3 and Sbv = 1) there was a reactivation of the ulcer
and the two others (miltefosine = 1 and Sbv = 1) had reactivation
of the infiltration in the borders of the healed ulcer.
To make sure that the absence of leishmania identification did
not influence the outcome, we compared the 6 month cure rate for
patients with negative culture or PCR versus those with positive
culture or PCR. In the miltefosine group, the cure rate of patients
with positive culture or PCR (n = 41) was 75.6% compared to
73.7% in the patients with negative culture or PCR (n = 19). In the
Sbv group, patients with positive culture or PCR (n = 23) had 47.8%
of cure rate compared to 71.4% in the patients with negative culture
or PCR (n = 7). However, the number of Sbv patients without
parasitological confirmation is very low to allow any conclusion.
Indeed if we exclude all parasitological negative patients from the
analysis of the primary outcome, the cure rate in the miltefosine
group (75.6%) is higher as compared to Sbv group (47.8%).
Miltefosine for L. braziliensis CL
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Figure 1. Trial flowchart.
doi:10.1371/journal.pntd.0000912.g001






(n =60) P value













Male/female 16/14 45/15 0.04
Number of male/female per age group 5/5 11/9 15/7 30/8 0.44 0.07
Age (years) 6 SD (range) 22.7614.7 (7–65) 22.0615.2 (4–59) 0.85







No. of lesions per age group NA NA
1 8 19 15 27
2 0 0 6 7
3 1 1 0 4
4 1 0 1 0
5 0 0 0 0
Area of lesion (mm2) 6 SD 410.6 461.2 0.47
doi:10.1371/journal.pntd.0000912.t001
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Toxicity and Tolerability
The frequency of AE was similar in the Sbv and miltefosine
groups (76.7% vs. 78.3%, p = 0.86) but they were reported more
commonly in patients $13 years-old than those ,13 years-old
(88.3% vs. 66.7%, p = 0.07). Although the detection of AE was
similar, the type of side effects varied widely between the treatment
arms (Table 3). The AE that were significantly more frequent in
the miltefosine group were vomiting (41.7%), nausea (40%) and
abdominal pain (23.3%). In the Sbv group, arthralgias (20.7%),
mialgias (20.7%) and fever (23.3%) were significantly more
frequent than in the miltefosine group (Table 3). Others common
AE were diarrhea (10% of miltefosine patients) and headache
(43% of Sbv patients). None of the reported AE required complete
discontinuation of therapy in any patient. In the miltefosine group,
one patient presented CTC grade 3 vomiting (6 episodes in 24 hrs
but did not require IV fluids) and other patient grade 3 diarrhea
(increase of $7 stools per day over baseline and interfering with
activities of daily living, but did not require hospitalization). Both
were able to continue the treatment with miltefosine after a period
of 3 to 5 days of interruption and oral fluid supplementation. One
patient in the Sbv group presented one episode of CTC grade 3
urticaria at the end of therapy. This patient needed to use oral
antihistaminic for 7 days with total regression of urticaria.
Mild and transient raised liver enzymes was detected in less than
5% of patients in both groups. No raised levels of urea and
creatinine or sodium and potassium abnormalities were detected
(data not shown).
Discussion
The treatment of CL caused by L. braziliensis with Sbv in rural
endemic areas in Brazil has been associated with decreasing cure
rates, in a setting where the parenteral route can be implicated
with unsatisfactory adherence. Additionally, the monotherapy of
CL with Sbv after several decades may induce Leishmania
resistance. It also has been shown that CL caused by L. braziliensis
Table 2. Follow-up endpoints results in patients with CL
treated with Sbvor miltefosine.
Follow-up endpoints Sbv Miltefosine P value
N=30 N=60
End of Treatment 20 days 28 days
Apparent cure (%) 1 (3.3) 1 (1.7) 0.61
Failure (%) 29 (96.7) 59 (98.3)
Lost in follow-up (%) 0 0
2 months after treatment
Apparent cure (%) 18 (60.0) 49 (81.7) 0.03
Failure (%) 12 (40.0) 11 (18.3)
Lost in follow-up (%) 1 2
6 months after treatment
Definitive cure (%) 16 (53.3) 45 (75.0) 0.04
Clinical Failure (%) 14 (46.7) 15 (25.0)
Lost in follow-up (%) 1 2
95% CI of cure rate 35.5% to 71.2% 64.0% to 86.0%
Difference in cure rate and
95% CI 21.7% (0.08 to 42.7)
doi:10.1371/journal.pntd.0000912.t002
Table 3. Clinical Toxicity Data in patients with CL treated with Sbv or miltefosine.




(N=60) CTC Grade P value**




Nausea 3 (10.0) 1 24 (40.0) 1 (18)
2 (6)
0.003
Abdominal pain 0 (0) _ 14 (23.3) 1 (14) 0.004
Diarrhea





Epigastralgia 2 (6.7) 1 5 (8.6) 1 (5) 1.0
Headache 13 (43.3) 1 (9)
2 (4)
17 (28.3) 1 (15)
2 (2)
0.17
Dizziness 4 (13.3) 1 (3)
2 (1)
8 (13.3) 1 (7)
2 (1)
1.0
Arthralgias 6 (20.7) 1 (3)
2 (3)
0 (0) _ 0.001
Mialgias 6 (20.7) 1 (3)
2 (3)
0 (0) _ 0.001
Fever 7 (23.3) 1 (5)
2 (2)
2 (3.3) 1 (2) 0.006
Anorexia 5 (16.7) 1 7 (11.7) 1 (7) 0.5
Urticaria 3 (10.0) 1 (2)
3 (1)
1 (1.7) 2 (1) 0.1
*In parenthesis, the number absolute of patients for each CTC grade.
**P was obtained comparing the incidence of each symptoms between miltefosine and Sbv groups.
doi:10.1371/journal.pntd.0000912.t003
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has higher therapeutic failure when compared to CL due to other
Leishmania species [15]. Therefore the development of new
therapeutic strategies associated to a better patient compliance and
higher efficacy is needed to a better control of CL.
Our study is the first to evaluate the efficacy of miltefosine in CL
caused by L. braziliensis in adults and children in Brazil. Our data
shows that a better therapeutic outcome is found after miltefosine
treatment with 75% of cure, compared to 53% in the Sbv group
irrespective of the age group. While we found no difference
between Sbv (70%) and miltefosine (68%) cure rates in children,
we observed that in patients above 12 years-old the superiority of
miltefosine is higher, with 79% of cure compared to 45% with Sbv
treatment. The reasons for miltefosine be more effective than
antimony on adults and have similar efficacy in children is not
completely understood. A decrease in the efficacy of miltefosine in
children could be explained by the difficulty to ingest the capsules
and also by differences in the biodisposition of the drug in
children. However, the efficacy of miltefosine in children and
adults was similar in the present study, and the difference found in
cure rates of miltefosine and Sbv was due to the high rate of
antimony failure in the adult population. It can not be ruled out
that no difference between the two drugs was documented in the
children population due to the small number of children in the
study, and consequently lack of power to detect the differences.
Alternatively the genetic polymorphism of L. braziliensis could
explain the decreased susceptibility to Sbv in isolates infecting the
adult population. We have shown that L. braziliensis is polymorphic
in the endemic region of Corte de Pedra [14], and severe forms of
the disease with lower response to antimony therapy are observed
predominantly in the adult population with agricultural labor
[3,4,16]. For instance, in disseminated leishmaniasis less than 40%
of patients are cured with one Sbv course [4], and atypical CL
failure to Sbv treatment is documented in up to 95% of the
patients [16].
Although the use of miltefosine is associated with several AE (as
well as Sbv therapy), we reported no SAE or biochemical
abnormalities that caused treatment to be abandoned. Miltefosine
is a safe and effective oral treatment of CL caused by L. braziliensis
in Bahia, Brazil and should be regarded as an option for CL
therapy in rural endemic areas of L. braziliensis transmission in
Brazil.
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